Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2CO3.Ca.Mg |
| Molecular Weight | 184.401 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].[Ca++].[O-]C([O-])=O.[O-]C([O-])=O
InChI
InChIKey=HHSPVTKDOHQBKF-UHFFFAOYSA-J
InChI=1S/2CH2O3.Ca.Mg/c2*2-1(3)4;;/h2*(H2,2,3,4);;/q;;2*+2/p-4
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8342726 | https://www.ncbi.nlm.nih.gov/pubmed/3415787 | https://www.ncbi.nlm.nih.gov/pubmed/23115717
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8342726 | https://www.ncbi.nlm.nih.gov/pubmed/3415787 | https://www.ncbi.nlm.nih.gov/pubmed/23115717
Calcium magnesium carbonate (dolomite), a mineral with the chemical formula CaMg(CO3)2, is made up of 60% calcium carbonate (equivalent to 24% calcium) and 40% magnesium carbonate (equivalent to 12% magnesium). It is recommended by lay periodicals as a desirable source of calcium and magnesium, but found to be also a source of potentially toxic heavy metals. Exposure to high atmospheric concentrations of this compound is likely to be associated with respiratory symptoms.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Alert to users of calcium supplements as antihypertensive agents due to trace metal contaminants. | 1988 Jul |
|
| Antitumoral effect of bleomycin+dolomite combination treatment, in mice bearing Ehrlich ascites carcinoma. | 1993 Sep-Oct |
|
| Dolomite supplementation improves bone metabolism through modulation of calcium-regulating hormone secretion in ovariectomized rats. | 2005 |
|
| Antiviral activities of heated dolomite powder. | 2008 Dec |
|
| Effects of calcium magnesium carbonate and roughage level on feedlot performance, ruminal metabolism, and site and extent of digestion in steers fed high-grain diets. | 2008 Nov |
|
| Effect of dolomite oral exposure in Wistar rats during organogenesis period of pregnancy. | 2008 Sep |
|
| Effect of dolomite on the repair of bone defects in rats: histological study. | 2010 Dec |
|
| Nanotoxicity of dolomite mineral of commercial importance in India. | 2011 Feb |
|
| Evaluation of cytotoxic, oxidative stress, proinflammatory and genotoxic responses of micro- and nano-particles of dolomite on human lung epithelial cells A(549). | 2012 Sep |
|
| Comparative cytotoxicity of dolomite nanoparticles in human larynx HEp2 and liver HepG2 cells. | 2015 Jun |
Patents
Sample Use Guides
Dolomite powder contained particles of different shapes and size both microparticles (MPs) and nanoparticles (NPs), suggesting potential occupational exposure of these particles. An attempt was therefore, made to investigate dolomite toxicity in a particle size-dependent manner in human lung epithelial cells A(549). cytotoxicity profiles were estimated by exposing cells at concentration doses 100–1000 ug/ml by two different methods. LC50 values of MPs were 655 ug/ml and 675 ug/ml whereas for NPs were 278 ug/ml and 300 ug/ml in MTT and Trypan blue assays, respectively.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
1574 (Number of products:2)
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID70892191
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
PRIMARY | |||
|
7000-29-5
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
PRIMARY | |||
|
61833
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
PRIMARY | |||
|
230-274-9
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
PRIMARY | |||
|
SUB33635
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
PRIMARY | |||
|
696
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
PRIMARY | |||
|
UG9H2002BF
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
PRIMARY | |||
|
C028042
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
PRIMARY | |||
|
806
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
PRIMARY | |||
|
100000127590
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
PRIMARY | |||
|
240-440-2
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
ALTERNATIVE | |||
|
23622
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
PRIMARY | RxNorm | ||
|
16389-88-1
Created by
admin on Fri Dec 15 21:31:14 GMT 2023 , Edited by admin on Fri Dec 15 21:31:14 GMT 2023
|
ALTERNATIVE |
SUBSTANCE RECORD
